[EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
申请人:CEPHALON INC
公开号:WO2010071885A1
公开(公告)日:2010-06-24
The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein.
As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
[EN] CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS<br/>[FR] COMPOSÉS AROMATIQUES CYCLOPROPANECARBOXAMIDO-SUBSTITUÉS UTILISABLES EN TANT QU'AGENTS ANTI-TUMORAUX
申请人:CROWN BIOSCIENCE INC TAICANG
公开号:WO2014000418A1
公开(公告)日:2014-01-03
Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.
The present invention provides a compound of formula I
or a salt form thereof, wherein Q
1
, Q
2
, Q
3
, and Q
4
are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.